BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu TTL, Gupta P, Ronfard V, Vertès AA, Bayon Y. Recent Progress in European Advanced Therapy Medicinal Products and Beyond. Front Bioeng Biotechnol 2018;6:130. [PMID: 30298129 DOI: 10.3389/fbioe.2018.00130] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Cho E, Yoo SL, Kang Y, Lee JH. Reimbursement and pricing of regenerative medicine in South Korea: key factors for achieving reimbursement. Regen Med 2020;15:1550-60. [PMID: 32356480 DOI: 10.2217/rme-2020-0035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 O'Donnell BT, Ives CJ, Mohiuddin OA, Bunnell BA. Beyond the Present Constraints That Prevent a Wide Spread of Tissue Engineering and Regenerative Medicine Approaches. Front Bioeng Biotechnol 2019;7:95. [PMID: 31134194 DOI: 10.3389/fbioe.2019.00095] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]
3 Del Pozo-Rodríguez A, Rodríguez-Gascón A, Rodríguez-Castejón J, Vicente-Pascual M, Gómez-Aguado I, Battaglia LS, Solinís MÁ. Gene Therapy. Adv Biochem Eng Biotechnol 2020;171:321-68. [PMID: 31492963 DOI: 10.1007/10_2019_109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
4 [DOI: 10.1101/587691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Zampirolli Dias C, Godman B, Gargano LP, Azevedo PS, Garcia MM, Souza Cazarim M, Pantuzza LLN, Ribeiro-Junior NG, Pereira AL, Borin MC, de Figueiredo Zuppo I, Iunes R, Pippo T, Hauegen RC, Vassalo C, Laba TL, Simoens S, Márquez S, Gomez C, Voncina L, Selke GW, Garattini L, Kwon HY, Gulbinovic J, Lipinska A, Pomorski M, McClure L, Fürst J, Gambogi R, Ortiz CH, Canuto Santos VC, Araújo DV, Araujo VE, Acurcio FA, Alvares-Teodoro J, Guerra-Junior AA. Integrative Review of Managed Entry Agreements: Chances and Limitations. Pharmacoeconomics 2020;38:1165-85. [PMID: 32734573 DOI: 10.1007/s40273-020-00943-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
6 Papasavva P, Kleanthous M, Lederer CW. Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases. Mol Diagn Ther 2019;23:201-22. [PMID: 30945166 DOI: 10.1007/s40291-019-00392-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 8.5] [Reference Citation Analysis]
7 Rühle A, Lopez Perez R, Zou B, Grosu AL, Huber PE, Nicolay NH. The Therapeutic Potential of Mesenchymal Stromal Cells in the Treatment of Chemotherapy-Induced Tissue Damage. Stem Cell Rev Rep 2019;15:356-73. [PMID: 30937640 DOI: 10.1007/s12015-019-09886-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
8 Green FR, Shubber NM, Koumpa FS, Hamilton NJI. Regenerative medicine for end-stage fibrosis and tissue loss in the upper aerodigestive tract: a twenty-first century review. J Laryngol Otol 2021;135:473-85. [PMID: 33988100 DOI: 10.1017/S002221512100092X] [Reference Citation Analysis]
9 Horgan D, Metspalu A, Ouillade MC, Athanasiou D, Pasi J, Adjali O, Harrison P, Hermans C, Codacci-Pisanelli G, Koeva J, Szucs T, Cursaru V, Belina I, Bernini C, Zhuang S, McMahon S, Toncheva D, Thum T. Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion. Biomed Hub 2020;5:130-52. [PMID: 33987187 DOI: 10.1159/000511678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Shammaa R, El-Kadiry AE, Abusarah J, Rafei M. Mesenchymal Stem Cells Beyond Regenerative Medicine. Front Cell Dev Biol. 2020;8:72. [PMID: 32133358 DOI: 10.3389/fcell.2020.00072] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 23.0] [Reference Citation Analysis]